Sanofi (India) on Monday said that it has received marketing authorization for its diabetes drug Soliqua (in pre-filled pen) from the Central Drugs Standard Control Organization (CDSCO).

Soliqua is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes who are insufficiently controlled on oral or injectable therapies. It comes in once daily dosing of pre-filled pens in fixed-ratio combination of 10-40 and 30-60 of insulin glargine and lixisenatide.

“With approximately 74 million Indians between the ages of 20-79 years living with diabetes, healthcare professionals need more treatment options to customize diabetes care for them. Soliqua is the latest addition to our comprehensive diabetes portfolio (OADs and insulins) indicated for people with obesity who are living with insufficiently controlled diabetes,” said Cyrus Aibara, head, Diabetes Business Unit, Sanofi (India)

“The global Solimix study that included Indian patients, demonstrated that once daily Soliqua provides with weight benefit and less hypoglycaemia when compared with twice daily premixed insulin – thereby becoming a valuable option for endocrinologists,” said Dr. Shalini Menon, Country Medical. Lead, Sanofi (India).